Trastuzumab has been combined with cytotoxics, hormones, other monoclonal antibodies, such a pertuzumab and bevacizumab ... trastuzumab is the first monoclonal antibody to become available.

Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.

The lead bispecific antibody candidate in Merus’s ... resistant to HER2-targeted therapies than Herceptin (trastuzumab) plus Perjeta (pertuzumab). A phase 1/2 clinical trial is ongoing in ...

Therapies that specifically target HER2 include Herceptin (trastuzumab), Perjeta (pertuzumab), and T-DM1 ... with chemotherapy and an additional antibody therapy. Many people ask about alternative ...

Roche has been developing an expensive antibody-based combination therapy of Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy in this indication. But results announced at last month ...

Post-surgical treatment with chemotherapy and the antibody trastuzumab, which binds to HER2, can significantly reduce the risk of recurrence in these patients. But the side effects can have a ...

In breast cancer, to aim for curative therapy, blocking more than the pathway targeted by the monoclonal antibody, trastuzumab, will be required. Given the likelihood of cross-talk between the ...

The new range of anti-pertuzumab antibodies includes monovalent Fab format antibodies suitable for the development of a pharmacokinetic bridging ELISA to measure free drug, as well as fully human IgG1 ...